文献速递肝病

肝纤维化与多种心血管代谢疾病危险因素相关:弗雷明汉心脏研究

Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
PubMed 文献 · Hepatology · 2021-02-06

在3276名弗雷明汉心脏研究成人参与者中,采用振动控制瞬时弹性成像评估肝脂肪变和肝纤维化,发现肝纤维化与肥胖、代谢综合征、糖尿病、高血压及低高密度脂蛋白胆固醇等多种心血管危险因素相关,且独立于年龄、性别、吸烟、饮酒、体力活动、转氨酶和肝脂肪变。

要点

  • 肝纤维化(LSM≥8.2 kPa)患病率为8.8%,肝脂肪变(CAP≥290 dB/m)患病率为28.8%。
  • 肝纤维化与肥胖(OR 1.82)、代谢综合征(OR 1.49)、糖尿病(OR 2.67)、高血压(OR 1.52)、低高密度脂蛋白胆固醇(OR 1.47)相关。
  • 需进一步纵向研究确定肝纤维化是否促进心血管危险因素或事件的发生。

核心结论

  • 在社区队列中,VCTE定义的肝纤维化与多种心血管危险因素相关,包括肥胖、代谢综合征、糖尿病、高血压和高密度脂蛋白胆固醇,即使校正协变量和CAP后仍存在关联。
  • 需要额外的纵向研究来确定肝纤维化是否促进新发心血管疾病危险因素或事件。

研究设计与样本

  • 研究纳入3276名弗雷明汉心脏研究成人参与者(53.9%为女性,平均年龄54.3±9.1岁),进行常规研究访视。
  • 采用振动控制瞬时弹性成像(VCTE)评估受控衰减参数(CAP;测量肝脂肪变)和肝脏硬度测量(LSM)。
  • 采用多变量校正逻辑回归模型分析LSM与肥胖相关、血管相关、血糖相关和胆固醇相关心血管危险因素之间的关联。

主要发现

  • 肝脂肪变(CAP≥290 dB/m)患病率为28.8%,肝纤维化(LSM≥8.2 kPa)患病率为8.8%。
  • 肝纤维化与肥胖的比值比(OR)为1.82(95% CI 1.35-2.47)。
  • 肝纤维化与代谢综合征的OR为1.49(95% CI 1.10-2.01)。
  • 肝纤维化与糖尿病的OR为2.67(95% CI 1.21-3.75)。
  • 肝纤维化与高血压的OR为1.52(95% CI 1.15-1.99),与低高密度脂蛋白胆固醇的OR为1.47(95% CI 1.09-1.98),校正年龄、性别、吸烟状态、每周酒精饮料、体力活动指数、转氨酶和CAP后。

关键数值与推荐

  • 肝脂肪变定义为CAP≥290 dB/m。
  • 肝纤维化定义为LSM≥8.2 kPa。
  • 校正变量包括年龄、性别、吸烟状态、每周酒精饮料、体力活动指数、转氨酶和CAP。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外的纵向研究来确定肝纤维化是否促进新发心血管疾病危险因素或事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is increasing in prevalence and will soon be the most common chronic liver disease. Liver stiffness, as assessed by vibration-controlled transient elastography (VCTE), correlates with hepatic fibrosis, an important predictor of liver-related and all-cause mortality. Although liver fat is associated with cardiovascular risk factors, the association between hepatic fibrosis and cardiovascular risk factors is less clear. APPROACH AND RESULTS: We performed VCTE, assessing controlled attenuation parameter (CAP; measure of steatosis) and liver stiffness measurement (LSM) in 3,276 Framingham Heart Study adult participants (53.9% women, mean age 54.3 ± 9.1 years) presenting for a routine study visit. We performed multivariable-adjusted logistic regression models to determine the association between LSM and obesity-related, vascular-related, glucose-related, and cholesterol-related cardiovascular risk factors. The prevalence of hepatic steatosis (CAP ≥ 290 dB/m) was 28.8%, and 8.8% had hepatic fibrosis (LSM ≥ 8.2 kPa). Hepatic fibrosis was associated with multiple cardiovascular risk factors, including increased odds of obesity (OR, 1.82; 95% CI, 1.35-2.47), metabolic syndrome (OR, 1.49; 95% CI 1.10-2.01), diabetes (OR, 2.67; 95% CI, 1.21-3.75), hypertension (OR, 1.52; 95% CI, 1.15-1.99), and low high-density lipoprotein cholesterol (OR, 1.47; 95% CI, 1.09-1.98), after adjustment for age, sex, smoking status, alcohol drinks/week, physical activity index, aminotransferases, and CAP. CONCLUSIONS: In our community-based cohort, VCTE-defined hepatic fibrosis was associated with multiple cardiovascular risk factors, including obesity, metabolic syndrome, diabetes, hypertension, and high-density lipoprotein cholesterol, even after accounting for covariates and CAP. Additional longitudinal studies are needed to determine if hepatic fibrosis contributes to incident cardiovascular disease risk factors or events.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Long MT, Zhang X, Xu H, et al. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology. 2021. PMID: 33125745. doi:10.1002/hep.31608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。